New draft guidance will streamline biosimilar development by reducing unnecessary testing, potentially saving developers up to $20 million per drug and helping lower costs for patients needing complex treatments.
🔗
https://www.fda.gov/news-events/press-announcements/fda-takes-further-steps-streamline-biosimilar-development-and-make-medicines-more-affordable
#FDAAlert #HealthNews 🌿
